Glaukos is a medical devices business based in the US. Glaukos shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Glaukos employs 907 staff and has a trailing 12-month revenue of around $326.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $117.65 |
|---|---|
| 52-week range | $59.22 - $126.96 |
| 50-day moving average | $114.75 |
| 200-day moving average | $91.37 |
| Wall St. target price | $122.82 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.89 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $117.65 from 2024-07-25
| 1 week (2024-07-19) | -2.55% |
|---|---|
| 1 month (2024-06-27) | 0.23% |
| 3 months (2024-04-26) | 18.26% |
| 6 months (2024-01-26) | 27.16% |
| 1 year (2023-07-27) | 51.22% |
|---|---|
| 2 years (2022-07-27) | 123.63% |
| 3 years (2021-07-27) | 144.09% |
| 5 years (2019-07-26) | 54.32% |
Valuing Glaukos stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Glaukos's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $326.4 million |
|---|---|
| Gross profit TTM | $213.9 million |
| Return on assets TTM | -7.95% |
| Return on equity TTM | -29.37% |
| Profit margin | -43.16% |
| Book value | $9.04 |
| Market Capitalization | $6.6 billion |
TTM: trailing 12 months
We're not expecting Glaukos to pay a dividend over the next 12 months.
Over the last 12 months, Glaukos's shares have ranged in value from as little as $59.22 up to $126.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos's is 1.061. This would suggest that Glaukos's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.